Results 201 to 210 of about 168,641 (363)

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Natriuretski peptidi u kliničkoj praksi [PDF]

Vojnosanitetski Pregled, 2005
Matunović Radomir, Stojanović Aleksandar, Damjanović Milorad   +2 more
doaj   +1 more source

C-Type Natriuretic Peptide (CNP) Could Improve Sperm Motility and Reproductive Function of Asthenozoospermia. [PDF]

Int J Mol Sci, 2022
Li N, Dong X, Fu S, Wang X, Li H, Song G, Huang D.   +6 more
europepmc   +1 more source

Effect of a unique chimeric peptide synthesized from brain natriuretic peptide and C-type natriuretic peptide on afferent arteriole

, 1998
Chao Wei
openalex   +1 more source

Identification of a potent serum factor that causes desensitization of the receptor for C-Type natriuretic peptide. [PDF]

, 2003
Ted D. Chrisman, Dorenda T Perkins, David L. Garbers   +2 more
openalex   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

C-Type Natriuretic Peptide Acts as a Microorganism-Activated Regulator of the Skin Commensals Staphylococcus epidermidis and Cutibacterium acnes in Dual-Species Biofilms. [PDF]

Biology (Basel), 2023
Ovcharova MA, Schelkunov MI, Geras'kina OV, Makarova NE, Sukhacheva MV, Martyanov SV, Nevolina ED, Zhurina MV, Feofanov AV, Botchkova EA, Plakunov VK, Gannesen AV.   +11 more
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3–Related Dwarfism

Journal of Pharmacology and Experimental Therapeutics, 2015
D. Wendt, M. Dvorak-Ewell, S. Bullens, F. Lorget, S. Bell, Jeff W. Peng, S. Castillo, M. Aoyagi-Scharber, C. O’Neill, P. Krejcí, W. Wilcox, D. Rimoin, S. Bunting   +12 more
semanticscholar   +1 more source

Endothelium-derived C-type natriuretic peptide offsets the pathogenesis of pulmonary hypertension

Pharmacological Research
In the systemic circulation, C-type natriuretic peptide (CNP) fulfils a multimodal homeostatic function, modulating many processes relevant to pulmonary hypertension (PH), including local blood flow, vascular remodeling and cardiac function.
Joshua P. Dignam, Aisah A. Aubdool, Vanessa R. Lowe, C. Perez-Ternero, Amie J. Moyes, Reshma S. Nahal, Jigisha A. Patel, Lucie H. Clapp, Mario Böhm, Ralph T. Schermuly, Adrian J. Hobbs   +10 more
doaj